Introduction
============

Gastric cancer is the fifth commonest cancer and the third leading cause of cancer-related death in the world.[@ref1] About 75% of the cases appear in Asia, particularly in Korea, China, and Japan.[@ref2],[@ref3] For several decades, these Eastern Asian countries have made efforts to overcome gastric cancer. To reduce morbidity, *Helicobacter pylori* eradication is now widely conducted. In Japan, potassium-competitive acid blocker-containing triple therapy showed high efficacy for the eradication compared to proton pump inhibitor-containing therapy.[@ref4],[@ref5] Furthermore, its decreasing infection rate in the younger generation will lead to the lower prevalence of gastric cancer in the future.[@ref6],[@ref7] To reduce gastric cancer-related mortality, several screening methods for early detection, such as X-ray, endoscopy, and the combination of *H. pylori* antibody and pepsinogen I and II, are performed.[@ref8]-[@ref10] Recently in Japan, over half of gastric cancers were detected as early gastric cancers (EGCs),[@ref11] which are defined as a malignant lesion of the stomach that is confined to the mucosa or submucosa layer, regardless of the lymph node metastasis (LNM) status.[@ref12] In Korea, the rate of detection in the early stage of gastric cancer has increased up to 70%.[@ref13],[@ref14]

Endoscopic resection (ER) is divided into endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). EMR is widely accepted as a minimally invasive treatment method for EGCs with a negligible risk of LNM,[@ref11],[@ref15]-[@ref18] and it provides a better quality of life. ESD has become the standard endoscopic technique as it allows *en bloc* resection of lesions irrespective of size and thereby permitting precise histopathological assessment of the resected specimen.[@ref19]-[@ref23] ESD has become the standard method, instead of EMR, in Eastern Asian countries. In fact, over 90% of ER for EGCs is ESD in Japan.[@ref24] Given its potential advantages over EMR, this procedure has begun to gain traction in some Western countries as well.[@ref25]

With the development of the ESD technique since the first English report in 1999,[@ref26] the indication of ER for EGCs has expanded. Moreover, recent reports revealed the long-term outcome and the risk of gastric cancer-related mortality for each curability criterion in the guidelines. This review focuses on up-to-date information about gastric ESD, particularly in EGCs that do not meet the curability criteria for ER.

CURABILITY IN THE GUIDELINES
============================

The curability criteria for ER of EGCs have been defined in the European, Korean, and Japanese guidelines.[@ref25],[@ref27]-[@ref29] Based on the risk of LNM, the guidelines classified the curability after ER for EGCs into three groups: curative resection for tumors of absolute indication, curative resection for tumors of expanded indication, and noncurative resection ([Table 1](#T1){ref-type="table"}).[@ref25],[@ref27]-[@ref29] *En bloc* resection with no lymphovascular invasion and negative resection margins are required for curative resection or expanded curative resection. Additionally, curative resection is appropriate for differentiated, intramucosal cancer measuring ≤2 cm in diameter without ulceration. It is regarded as an expanded curative resection when the lesion is (1) differentiated, intramucosal cancer measuring \>2 cm in diameter and without ulceration; (2) differentiated, mucosal cancer measuring ≤3 cm with ulceration; (3) undifferentiated, mucosal cancer measuring ≤2 cm without ulceration; (4) differentiated cancer measuring ≤3 cm with a submucosal invasion depth of \<500 µm (pT1b(SM1)). Undifferentiated cancer includes poorly-differentiated adenocarcinoma or signet ring cell carcinoma. Recently, the Japanese guidelines were updated,[@ref30] but are now available only in Japanese. In the guidelines, curability was divided into A (curative resection), B (expanded curative resection), and C (noncurative resection) ([Table 2](#T2){ref-type="table"}).[@ref30] Based on the favorable results in a multicenter prospective study,[@ref31] (1) and (2) of the criteria in expanded curative resection were regarded as curability A in the latest guidelines ([Table 2](#T2){ref-type="table"}).[@ref30] Curability C was subdivided into curability C-1 and C-2: curability C-1 corresponds to noncurative resection with a merely positive horizontal margin or piecemeal resection, and curability C-2 corresponds to the others. In addition, since differentiated EGC with a minor undifferentiated component in the submucosa has risk of LNM,[@ref32] this was regarded as curability C-2 in the latest guidelines.[@ref30]

CURATIVE RESECTION AND EXPANDED CURATIVE RESECTION
==================================================

1. Risk of LNM
--------------

The criteria of curative resection and expanded curative resection are mainly based on the reports by Gotoda *et al*.[@ref33] and Hirasawa *et al*.[@ref34] These reports analyzed a large series of EGCs and did not find any LNMs when EGCs meet the criteria for curative resection and expanded curative resection.[@ref33],[@ref34] However, one of the major problems in this field is that most studies are from Korea and Japan. In fact, all of the included studies in a meta-analysis of LNM in the absolute and expanded criteria for ER were from Eastern Asian countries.[@ref35] Therefore, it is unclear whether these data can be extrapolated to the other countries. Recently, some studies have been reported from Western countries. In the national database of the United States, the rate of LNM in EGCs was 7.8%,[@ref36] which is higher than the LNM rates in large Asian series (2% to 5%).[@ref33],[@ref37],[@ref38] In addition, the rates of LNM for white (9.6%) and black (10.9%) patients in mucosal gastric cancers were almost double that of Asian/Pacific islanders (5.2%).[@ref36] The authors in this study suggested the existence of different biological aggressiveness in EGCs among racial/ethnic groups. A recent multicenter study in the United States including 176 patients with EGC also found a higher rate of LNM in EGCs; 0% (0/10) and 7.5% (3/40) in patients fulfilling the absolute and expanded curative resection criteria for ER, respectively.[@ref39] However, differentiated and non-ulcerated intramucosal lesions \>2 cm in diameter had no LNM. Thus, in Western countries, EGCs that meet the criteria for curative resection may have negligible risk for LNM. Among EGCs that meet the criteria for expanded curative resection, differentiated and non-ulcerated intramucosal gastric cancers \>2 cm in diameter may have little risk for LNM. On the other hand, EGCs with the other type of expanded curative resection may have a certain degree of risk for LNM in Western countries. The discrepancy between Eastern Asian and Western countries may be partly due to a difference in biological aggressiveness. However, in Western countries, specimens of ESD and surgery may not be handled with the same methodology as in Japan, suggesting that a slightly higher risk of LNM might be expected in these countries.[@ref40] In the Japanese guidelines,[@ref12] the tissue slice preparation is recommended to be 2 mm for ER and 5 to 7 mm for surgical resection. For evaluating the difference in LNM between Eastern Asian and Western countries appropriately, the standardization of specimen handling and histological evaluation will be necessary.

2. Long-term outcome and recurrence
-----------------------------------

In this review, recurrence is defined as tumor relapse in the lymph nodes and/or other organs after ER for EGCs. Many studies revealed a favorable long-term outcome in patients with curative resection and expanded curative resection.[@ref41]-[@ref47] A prospective multicenter cohort study from Korea revealed no gastric cancer-related mortality in 600 patients with curative resection and expanded curative resection of ESD during the follow-up duration.[@ref48] Concerning differentiated-type intramucosal gastric cancers that meet an expanded indication of ER, a prospective multicenter cohort study from Japan revealed that the 5-year overall survival (OS) was 97.0% and that no recurrence was observed in patients who satisfied the curative resection criteria.[@ref31] A prospective confirmatory trial for patients with ESD for undifferentiated-type EGCs that meet the expanded indication of ER also showed an excellent 5-year OS of 99.3%.[@ref49] In a large-scale multicenter retrospective study from Japan, recurrence was observed in 0% (0/6,456) and 0.14% (6/4,202) of patients with curative resection and expanded curative resection, respectively.[@ref50] Among cases with recurrence, pT1b(SM1), ulceration, and differentiated-predominant mixed histology were shown in three, three and three cases, respectively.[@ref50] A Korean large-scale single center study also showed that 0.14% (5/3,588) of patients with curative resection and expanded curative resection underwent recurrence after ESD.[@ref51] Another study from Korea reported 0.15% (2/1,306) of recurrence after curative resection and expanded curative resection.[@ref52] In these studies, most patients with curative resection and expanded curative resection have favorable long-term outcomes after ESD for EGC; however, it should be noted that a very small number of patients with expanded curative resection have recurrence.

In Western countries, a recent report from Germany recommended ESD for differentiated and non-ulcerated intramucosal lesions, due to the favorable long-term outcomes.[@ref53] However, data are lacking in the other type of expanded indication for ESD of EGC.

3. Management after ESD
-----------------------

Based on the reports about LNM in surgery and long-term outcome in ESD, the management after ESD should be different between Eastern Asian and Western countries. In Eastern Asian countries, patients with curative resection and expanded curative resection can be managed according to the Japanese guidelines, that is, endoscopic surveillance at intervals of 6 to 12 months for curative resection and endoscopic surveillance by endoscopy and computed tomography (CT) at intervals of 6 to 12 months for expanded curative resection ([Fig. 1](#F1){ref-type="fig"}).[@ref27],[@ref28],[@ref30]

In Western countries, patients with curative resection can be managed in the same way as in Eastern Asian countries. In expanded curative resection, differentiated and non-ulcerated intramucosal gastric cancer \>2 cm in diameter can be managed by endoscopic and CT surveillance, which is the same as in Eastern Asian countries. However, lesions with the other type of expanded curative resection might be regarded as noncurative resection that requires additional surgery, due to the potential risk of LNM ([Fig. 1](#F1){ref-type="fig"}).[@ref39]

NONCURATIVE RESECTION
=====================

1. Long-term outcome in two treatment strategies after noncurative resection
----------------------------------------------------------------------------

According to the guidelines,[@ref25],[@ref27]-[@ref30] additional surgery is the standard therapy for patients with noncurative resection after ER. However, according to two large-scale studies,[@ref54],[@ref55] about half of such patients select follow-up with no additional treatment after ESD. Many studies have evaluated the long-term outcomes of two treatment methods after noncurative resection of ER ([Table 3](#T3){ref-type="table"}).[@ref55]-[@ref61] All studies showed that the OS in patients with no additional treatment (72.0% to 85.0%) was lower than that in patients with additional surgery (85.0% to 96.0%).[@ref55],[@ref57]-[@ref61] However, this difference may be largely affected by a selection bias in the treatment strategy after ER because there is a discrepancy in the OS and disease-specific survival (DSS) between no additional treatment and additional surgery groups. In fact, the 5-year DSSs in patients with additional treatment and those with no additional treatment were 98.7% to 100% and 92.6% to 97.5%, respectively.[@ref55]-[@ref58],[@ref61] However, this is also affected by a selection bias in the treatment method after ER. According to a study using propensity-score matching analysis of the baseline characteristics for reducing this bias, additional surgery reduced cancer-specific mortality to one-third.[@ref62]

2. LNM in patients with additional surgery after noncurative resection
----------------------------------------------------------------------

The rate of LNM in patients who underwent additional surgery after noncurative resection of ER for EGC is reported to be 5.2% to 11.0%.[@ref53],[@ref54],[@ref57]-[@ref61],[@ref63]-[@ref70] Most reports are from Korea and Japan, and only one study has been reported from Western countries.[@ref53] In this study, LNM after noncurative resection was shown in 8.3% of the patients (1/12),[@ref53] which is similar to the rate of LNM (8.5%) in the largest study from Japan.[@ref64] However, it is difficult to detect LNM by preoperative CT. Actually, preoperative CT was not able to detect LNM in 90 % of patients with LNM.[@ref58]

Many studies reported the risk factors for LNM after noncurative resection of ER ([Table 4](#T4){ref-type="table"}).[@ref57]-[@ref59],[@ref63],[@ref64],[@ref66],[@ref67],[@ref69],[@ref70] In all studies evaluating the variable of lymphovascular invasion, this variable was a significant risk factor for LNM after ER with noncurative resection. In two studies that analyzed lymphatic and vascular invasions, separately,[@ref64],[@ref66] lymphatic invasion was the most important risk factor for LNM. Until now, tumor size \>30 mm, tumor invasion into the submucosa ≥500 µm from the muscularis mucosa (pT1b(SM2)), vascular invasion, positive vertical margin (VM), and macroscopic appearance of flat/elevated has been also reported as independent risk factors for LNM.

The undifferentiated-type of cancer was not a significant risk factor for LNM in all but one study ([Table 4](#T4){ref-type="table"}). However, a large-scale study about additional surgery for EGC with pT1b(SM2) after ESD clarified that an undifferentiated component in submucosal invasion was an independent risk factor for LNM, despite the fact that the undifferentiated-type was not a risk factor.[@ref71] Therefore, among undifferentiated-type EGC, a submucosal undifferentiated component may be important for LNM after ESD with noncurative resection. However, the results on the LNM rate in patients undergoing additional surgery after noncurative ER for undifferentiated-type EGC are different from the studies about gastrectomy as the initial treatment for EGC, which showed this as a risk factor for LNM.[@ref33] This discrepancy may be affected by a bias that arises from the initial treatment selection for EGC: surgical selection or ER. In fact, patients with undifferentiated-type EGC comprised 12.7% to 33.3% of the patients,[@ref57]-[@ref59],[@ref63],[@ref64],[@ref66],[@ref67],[@ref69],[@ref70] which is lower than the prevalence of undifferentiated-type EGC reported in previous studies of surgery for EGC (35.9% to 40.4%).[@ref72]-[@ref74] Therefore, we should be careful in interpreting the results concerning ESD with noncurative resection for undifferentiated-type EGC. Conversely, studies about gastrectomy as the initial treatment are also affected by selection bias. Thus, it should be noted that these studies also have this limitation.

3. Risk-scoring system for patients with noncurative resection
--------------------------------------------------------------

Based on the previous reports,[@ref53],[@ref54],[@ref57]-[@ref61],[@ref63]-[@ref70] LNM was not shown in 89.0% to 94.8% of patients who underwent additional surgery after noncurative ER for EGC. Accordingly, additional surgery for all such patients may be excessive and further risk stratification can be useful for deciding treatment strategy after ER.

Now, two risk-scoring systems are available. One is the eCura system from Japan ([Table 5](#T5){ref-type="table"}).[@ref64] This system was developed from the largest series of EGCs, involving 1,101 patients who underwent additional surgery after noncurative ESD. Based on the risk for LNM, weighted points were assigned for five pathological factors: 3 points for lymphatic invasion and 1 point each for tumor size \>30 mm, positive VM, pT1b(SM2), and vascular invasion. On the other hand, undifferentiated-type and ulceration had 0 points. In this system, total risk scores were categorized as low-risk (0--1 point), intermediate-risk (2--4 points), and high-risk (5--7 points) for LNM. The rates of LNM in each risk category were 2.5%, 6.7%, and 22.7%, respectively. Furthermore, when the eCura system was applied to patients with no additional treatment after noncurative ESD, the 5-year DSSs in each risk category were 99.6%, 96.0%, and 90.1%, respectively. In particular, the 5-year DSSs in patients with additional surgery and those with no additional treatment were similar in the low-risk category (99.7% vs 99.6%).[@ref75] Therefore, follow-up with no additional treatment for patients in the low-risk category of the eCura system may be an acceptable option, especially in some of elderly patients.

Another scoring system is from Korea ([Table 6](#T6){ref-type="table"}).[@ref69] This study analyzed 321 patients who underwent additional surgery after noncurative ER, and 2 points were assigned for lymphovascular invasion and 1 point each for female and positive VM. Then, the authors proposed algorism based on their results: 0 points (0% risk for LNM) for closed follow-up or endoscopic treatment, 1 point (1.9% risk) for relative indication for additional surgery, and ≥2 points (14.0% risk) for definite indication of additional surgery.

These risk-scoring systems provide important information for deciding the treatment strategy after noncurative ER. In fact, a recent study confirmed the efficacy of the eCura system for predicting the necessity of additional surgery after noncurative ESD.[@ref76] However, further external validation is needed in both scoring systems.

4. Recurrence in patients with no additional treatment after noncurative resection
----------------------------------------------------------------------------------

When patients select no additional treatment after noncurative ESD despite the guidelines' recommendation for additional surgery, such patients are at risk for recurrence. In the eCura system, the 5-year recurrence rates in the low-, intermediate-, and high-risk categories were 0.7%, 5.7%, and 11.7%, respectively.[@ref64] Furthermore, lymphatic invasion was mainly associated with early-phase recurrence, whereas vascular invasion was associated with late-phase recurrence.[@ref77] This information may help in deciding the treatment strategy in some elderly patients and/or those with severe underlying diseases. However, it should be noted that, when recurrence is detected in patients who were followed up with no additional treatment after noncurative ESD, most of them have a poor prognosis.[@ref78]

5. Recurrence in patients with additional surgery after noncurative resection
-----------------------------------------------------------------------------

Some patients have recurrence even after additional surgery for EGCs with noncurative ESD. In fact, a large-scale study reported that the 5-year DSS in patients who underwent additional surgery after noncurative ESD was 98.7%.[@ref55] Thus, since 1.3% of patients died of gastric cancer within 5 years even after undergoing additional surgery, it is necessary to identify high-risk patients for recurrence after additional surgery. To date, only one study has focused on this topic.[@ref79] According to this report, the combination of LNM and vascular invasion led to a high-risk of recurrence. When the status of LNM was subdivided into N0, N1, and N2/N3 according to the 8th edition of the AJCC TNM staging system for gastric cancer, patients with N0 had little risk for recurrence (0.3% to 0.5% in the 5-year) regardless of the status of vascular invasion. On the other hand, patients with N2/N3 had high-risk for recurrence; 42.9% in those with positive vascular invasion and 27.3% in those with negative vascular invasion in the 5-year. In patients with N1, recurrence after additional surgery depended on the status of vascular invasion; 19.4% in those with positive vascular invasion and 0.0% in those with negative vascular invasion. Thus, patients with N2/N3 and both N1 and vascular invasion may be at high-risk for recurrence after additional surgery.[@ref79] For such patients, further treatment, such as adjuvant chemotherapy, may be useful ([Fig. 2](#F2){ref-type="fig"}). However, the small number of cases with recurrence after additional surgery is the main limitation of this study. Hence, a further large-scale multicenter study will be needed to resolve this issue in future.

6. The role of lymphatic and vascular invasion for metastasis after noncurative resection
-----------------------------------------------------------------------------------------

Both lymphatic and vascular invasions play an important but different role in metastasis. lymphatic invasion is the highest risk factor for regional LNM in patients with noncurative ESD for EGCs.[@ref64] Conversely, lymphatic invasion did not affect the recurrence rate after additional gastrectomy with lymph node dissection.[@ref79] When follow-up without additional surgery was selected after noncurative ESD for EGCs, lymphatic invasion was an independent risk factor for recurrence, mainly as distant metastases.[@ref55] From these results, EGC with lymphatic invasion might metastasize to distant lymph nodes and/or other organs via regional LNM. Meanwhile, a large-scale study identified vascular invasion as an independent risk factor for regional LNM, although its significance was nearly borderline.[@ref64] On the other hand, vascular invasion had little risk of recurrence after additional surgery when regional LNM was absent, in contrast to the much higher risk for recurrence under the presence of regional LNM.[@ref79] Although its mechanism is unclear, the presence of cancer cells in veins with the capability of regional LNM may represent their aggressive nature to metastasize to distant lymph nodes and/or other organs.

7. Management after noncurative resection
-----------------------------------------

Additional surgery is the standard treatment after noncurative ESD.[@ref25],[@ref27]-[@ref30] Furthermore, when recurrence is found after selecting no additional treatment in noncurative ESD, most patients cannot achieve long-term survival.[@ref78] Thus, additional surgery should be selected in healthy, non-elderly patients ([Fig. 2](#F2){ref-type="fig"}). However, in some elderly patients and/or those with severe underlying diseases, the advantages and disadvantages of additional surgery should be considered when selecting the treatment strategy after noncurative ESD. In this regard, risk-scoring systems for LNM may facilitate the clinical decision in patients who underwent noncurative ESD. However, for treatment selection, not only the risk of LNM but also the condition of patients are taken into account. For example, additional surgery is sometimes avoided even in patients with a high-risk for LNM in the scoring system when the risk of surgery is regarded as too high. Furthermore, follow-up with no additional treatment is sometimes selected in patients who are not expected to have long-term survival. Since *H. pylori* prevalence rates are markedly lower in younger people compared to that in older people,[@ref6] the prevalence of gastric cancer will decrease but patients with gastric cancer will be older.[@ref80] In elderly patients with gastric cancer, it is necessary to evaluate not only the risk for LNM but also the condition of the patients because heterogeneity in the aging process leads to a diverse range of age-related declines in health and physical status among elderly patients. To date, several indices for evaluating the condition of patients, such as prognostic nutritional index,[@ref81],[@ref82] Charlson comorbidity index,[@ref81],[@ref83] and American Society of Anesthesiologists' Physical Status,[@ref84],[@ref85] have been reported as indicators for the prognosis in patients with EGCs. However, some reports have shown conflicting results.[@ref81],[@ref83]-[@ref86] Therefore, for deciding treatment strategy in elderly patients with noncurative resection of ESD for EGCs, the establishment of a reliable tool for predicting the prognosis is demanded.

SUMMARY AND CONCLUSIONS
=======================

In patients with expanded curative resection, the management should differ between Eastern Asian countries and Western countries: the Japanese guidelines can be applied to Eastern Asian countries, but additional surgery may be recommended for patients with undifferentiated-type, ulcerated, or pT1b(SM1) EGCs in Western countries. Among patients with noncurative ESD, additional surgery is recommended for all healthy, non-elderly patients. On the other hand, risk-scoring systems may help in selecting the treatment strategy after noncurative ESD in some elderly patients and/or those with severe underlying disease. In the future, a new tool for evaluating the condition of patients should be established.
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![Proposal for the management of patients undergoing endoscopic submucosal dissection with curative resection and expanded curative resection for early gastric cancers.\
pT1b(SM1), tumor invasion into the submucosa \<500 μm from the muscularis mucosa; CT, computed tomography.](GNL-14-412-f1){#F1}

![Proposal of the management strategy for endoscopic submucosal dissection with noncurative resection for early gastric cancers.\
V (+), positive vascular invasion; V (--), negative vascular invasion.](GNL-14-412-f2){#F2}

###### 

The Curability Criteria for ER of EGCs in the Japanese Guidelines (4th Version)[@ref28],\*

              Ulceration                              Differentiated-type                     Undifferentiated-type                                                            
  ----------- --------------------------------------- --------------------------------------- ---------------------------------------- --------------------------------------- --------
  pT1a        Negative                                ≤2 cm[†](#t1fn2){ref-type="table-fn"}   \>2 cm[†](#t1fn2){ref-type="table-fn"}   ≤2 cm[†](#t1fn2){ref-type="table-fn"}   \>2 cm
                                                                                                                                                                               
  Positive    ≤3 cm[†](#t1fn2){ref-type="table-fn"}   \>3 cm                                                                                                                   
                                                                                                                                                                               
  pT1b(SM1)   ≤3 cm[†](#t1fn2){ref-type="table-fn"}   \>3 cm                                                                                                                   
                                                                                                                                                                               
  pT1b(SM2)                                                                                                                                                                    
                                                                                                                                                                               

ER, endoscopic resection; EGCs, early gastric cancers; pT1b(SM1), a submucosal invasion depth of \<500 μm; pT1b(SM2), tumor invasion into the submucosa ≥500 μm from the muscularis mucosa.

White, gray, and black areas correspond to curative resection^†^, expanded curative resection^†^, and noncurative resection, respectively; ^†^Piecemeal resection or positive horizontal margin is regarded as noncurative resection.

###### 

The Curability Criteria for ER of EGCs in the Latest Version of Japanese Guidelines (Currently Available Only in Japanese)[@ref30],\*

              Ulceration                                                               Differentiated-type                      Undifferentiated-type                                                            
  ----------- ------------------------------------------------------------------------ ---------------------------------------- ---------------------------------------- --------------------------------------- --------
  pT1a        Negative                                                                 ≤2 cm[†](#t2fn2){ref-type="table-fn"}    \>2 cm[†](#t2fn2){ref-type="table-fn"}   ≤2 cm[†](#t2fn2){ref-type="table-fn"}   \>2 cm
                                                                                                                                                                                                                 
  Positive    ≤3 cm[†](#t2fn2){ref-type="table-fn"}                                    \>3 cm[†](#t2fn2){ref-type="table-fn"}                                                                                    
                                                                                                                                                                                                                 
  pT1b(SM1)   ≤3 cm[†](#t2fn2){ref-type="table-fn"},[‡](#t2fn2){ref-type="table-fn"}   \>3 cm                                                                                                                    
                                                                                                                                                                                                                 
  pT1b(SM2)                                                                                                                                                                                                      
                                                                                                                                                                                                                 

ER, endoscopic resection; EGCs, early gastric cancers; pT1b(SM1), submucosal invasion depth of \<500 μm; pT1b(SM2), tumor invasion into the submucosa ≥500 μm from the muscularis mucosa.

White, gray, and black areas correspond to curability A^†^, curability B^†^, and curability C-2, respectively; ^†^Piecemeal resection or positive horizontal margins is regarded as curability C-1; ^‡^A lesion with a submucosal undifferentiated component is regarded as curability C-2.

###### 

Long-Term Outcome of Patients Undergoing Noncurative ER for EGCs (≥100 Cases)

  Author (year)                   Country   No. of patients   No additional treatment, %   Median follow-up period, mo                                                       Additional surgery, %   No additional treatment, %                    
  ------------------------------- --------- ----------------- ---------------------------- --------------------------------------------------------------------------------- ----------------------- -------------------------------------- ------ --------------------------------------
  Hatta et al. (2017)[@ref55]     Japan     1,969             45.5                         66                                                                                92.6                    98.8                                   75.2   97.5
  Suzuki et al. (2017)[@ref57]    Japan     540               35.6                         76[\*](#t3fn2){ref-type="table-fn"}, 70[†](#t3fn2){ref-type="table-fn"}           94.7                    98.8                                   83.8   96.8
  Kawata et al. (2017)[@ref58]    Japan     506               36.2                         65[\*](#t3fn2){ref-type="table-fn"}, 61[†](#t3fn2){ref-type="table-fn"}           90.0                    98.7                                   72.0   96.5
  Kim et al. (2015)[@ref60]       Korea     274               29.2                         60.5                                                                              94.3                    99.5[‡](#t3fn2){ref-type="table-fn"}   85.0   97.0[‡](#t3fn2){ref-type="table-fn"}
  Yang et al. (2015)[@ref56]      Korea     267               53.9                         40.7                                                                              NA                      98.7                                   NA     97.4
  Yano et al. (2018)[@ref61]      Japan     231               48.9                         48                                                                                96.0                    100                                    73.3   92.6
  Kikuchi et al. (2017)[@ref59]   Japan     150               51.3                         4.8 yr[\*](#t3fn2){ref-type="table-fn"}, 4.7 yr[†](#t3fn2){ref-type="table-fn"}   85.0                    97.0[§](#t3fn2){ref-type="table-fn"}   79.4   95.3[§](#t3fn2){ref-type="table-fn"}

ER, endoscopic resection; EGC, early gastric cancers; OS, overall survival; DSS, disease-specific survival; NA, no assessment.

In patients with additional surgery after endoscopic submucosal dissection (ESD) with noncurative resection; ^†^In patients with no additional treatment after ESD with noncurative resection; ^‡^Total survival rate; ^§^Recurrence-free survival.

###### 

Risk Factors for LNM on Multivariate Analysis in Patients with Additional Surgery after ESD with Noncurative Resection for EGCs (≥100 Cases)

  Author (year)                            Country                No. of patients   Period   LNM rate, %   Risk factors                 OR (95% CI)
  ---------------------------------------- ---------------------- ----------------- -------- ------------- ---------------------------- -----------------------
  Hatta et al. (2017)[@ref64]              Japan                  1,101             00--11   8.5           Lymphatic invasion           3.99 (2.43--6.55)
  Tumor size \>30 mm                       2.03 (1.28--3.14)                                                                            
  Positive VM                              1.81 (1.10--3.00)                                                                            
  Vascular invasion                        1.65 (1.01--2.70)                                                                            
  Kim et al. (2017)[@ref70]                Korea                  350               04--14   8.57          Lymphovascular invasion      5.619 (2.400--13.153)
  pT1b(SM2)                                3.224 (1.320--7.876)                                                                         
  Suzuki et al. (2017)[@ref57]             Japan                  338               99--10   5.3           Positive VM with pT1b(SM2)   3.6 (1.3--10.2)
  Lymphovascular invasion                  3.5 (1.2--10.4)                                                                              
  Kawata et al. (2017)[@ref58]             Japan                  323               02--12   9.3           Lymphovascular invasion      8.57 (2.76--38.14)
  Jung et al. (2017)[@ref69]               Korea                  321               07--15   7.2           Lymphovascular invasion      8.701 (2.829--26.761)
  Positive VM                              3.753 (1.431--9.842)                                                                         
  Sunagawa et al. (2017)[@ref66]           Japan                  200               05--15   7.5           Lymphatic invasion           14.2 (1.41--16.8)
  Macroscopic appearance (flat/elevated)   4.63 (1.04--18.0)                                                                            
  Vascular invasion                        4.00 (1.04--18.0)                                                                            
  Toyokawa et al. (2016)[@ref67]           Japan                  100               04--13   9.0           Undifferentiated-type        45.58 (2.88--720.94)
  Lymphovascular invasion                  38.38 (1.94--761.43)                                                                         

LNM, lymph node metastasis; ESD, endoscopic submucosal dissection; EGCs, early gastric cancers; OR, odds ratio; CI, confidence interval; VM, vertical margin; pT1b(SM2), tumor invasion into the submucosa ≥500 μm from the muscularis mucosa.

###### 

Risk-Scoring System (eCura System) Used in Japan for Predicting LNM in Patients with Noncurative Resection after ESD for EGCs[@ref64]

  Total points[\*](#t5fn2){ref-type="table-fn"}   Rate of LNM, %   Risk category       Rate of LNM in risk categories, %
  ----------------------------------------------- ---------------- ------------------- -----------------------------------
  0                                               1.6              Low-risk            2.5
  1                                               2.6                                  
  2                                               4.9              Intermediate-risk   6.7
  3                                               7.4                                  
  4                                               8.3                                  
  5                                               19.9             High-risk           22.7
  6                                               27.3                                 
  7                                               26.7                                 

LNM, lymph node metastasis; ESD, endoscopic submucosal dissection; EGCs, early gastric cancers; pT1b(SM2), tumor invasion into the submucosa ≥500 μm from the muscularis mucosa.

Three points are assigned for lymphatic invasion, 1 point each for tumor size \>30 mm, positive vertical margins, pT1b(SM2), and vascular invasion, and 0 point each for undifferentiated-type and ulceration.

###### 

Risk-Scoring System from Korea Used in Predicting LNM in Patients with Noncurative Resection after ESD for EGCs[@ref30]

  Total points[\*](#t6fn2){ref-type="table-fn"}   Rate of LNM, %
  ----------------------------------------------- ----------------
  0                                               0.0
  1                                               1.9
  ≥2                                              14.0

LNM, lymph node metastasis; ESD, endoscopic submucosal dissection; EGCs, early gastric cancers.

Two points are assigned for lymphovascular invasion, 1 point each for positive vertical margin and female.
